The role of modulators in cystic fibrosis related diabetes

被引:26
|
作者
Merjaneh, Lina [1 ]
Hasan, Sana [2 ]
Kasim, Nader [3 ]
Ode, Katie Larson [4 ]
机构
[1] Seattle Childrens Hosp, Dept Pediat, Div Endocrinol, Seattle, WA USA
[2] Cleveland Clin Fdn, Dept Endocrinol & Metab, Cleveland, OH USA
[3] Helen Devos Childrens Hosp, Div Pediat Diabet & Endocrinol, Spectrum Hlth, Grand Rapids, MI USA
[4] Univ Iowa, Dept Pediat, Div Endocrinol, Stead Family Childrens Hosp, Iowa City, IA USA
关键词
CFRD; Modulator therapy; Insulin; INSULIN-SECRETION; TEZACAFTOR-IVACAFTOR; CHLORIDE CHANNEL; CFTR; EPIDEMIOLOGY; CHILDREN;
D O I
10.1016/j.jcte.2021.100286
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development and introduction of modulator therapies have completely shifted the paradigm for the treatment of cystic fibrosis (CF). Highly effective modulator therapies have driven marked improvements in lung function, exacerbation rate, weight and quality of life in CF patients. However, their effect on CF related diabetes (CFRD) is not well delineated. The role of CF transmembrane conductance regulator (CFTR) in CFRD pathogenesis is inadequately understood and research aimed at deciphering the underlying mechanisms of CFRD continues to evolve. In this review, we summarize what is known regarding the effect of CFTR modulators on CFRD. Small studies using ivacaftor monotherapy in gating mutations have revealed improvement in insulin secretion, glucose tolerance and/or decrease in insulin requirement. However, lumacaftor/ivacaftor studies (primarily in delta F 508 homozygous) have not revealed significant improvement in CFRD or glucose tolerance. No studies are yet available regarding the effect of the highly effective triple therapy (elexacaftor/tezacaftor/ivacaftor) on CFRD or insulin secretion. CFTR modulators might affect development or progression of CFRD through many mechanisms including improving insulin secretion by correcting the CFTR defect directly, improving ductal function, reducing islet inflammation, and improving incretin secretion or by enhancing insulin sensitivity via reduced systemic inflammation and increased physical activity driven by improved lung function and quality of life. On the other hand, they can stimulate appetite and improve gastrointestinal function resulting in increased caloric intake and absorption, driving excessive weight gain and potentially increased insulin resistance. If the defect in insulin secretion is reversible then it is possible that initiation of CFTR modulators at a younger age might help prevent CFRD. Despite the advances in CF management, CFRD remains a challenge and knowledge continues to evolve. Future studies will drive better understanding of the role of highly effective CFTR modulators in CFRD.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Cystic fibrosis-related diabetes: optimizing care with a multidisciplinary approach
    Frost, Freddy
    Dyce, Paula
    Ochota, Alicja
    Pandya, Sejal
    Clarke, Thomas
    Walshaw, Martin J.
    Nazareth, Dilip S.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 545 - 552
  • [42] Diagnosing cystic fibrosis-related diabetes: current methods and challenges
    Prentice, Bernadette
    Hameed, Shihab
    Verge, Charles F.
    Ooi, Chee Y.
    Jaffe, Adam
    Widger, John
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (07) : 799 - 811
  • [43] Vitamin D deficiency as a risk factor for cystic fibrosis-related diabetes in the Scandinavian Cystic Fibrosis Nutritional Study
    Pincikova, T.
    Nilsson, K.
    Moen, I. E.
    Fluge, G.
    Hollsing, A.
    Knudsen, P. K.
    Lindblad, A.
    Mared, L.
    Pressler, T.
    Hjelte, L.
    DIABETOLOGIA, 2011, 54 (12) : 3007 - 3015
  • [44] Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis
    Wang, Xueqing
    Tse, Chris
    Singh, Ashvani
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 2255 - 2300
  • [45] Cystic Fibrosis in the Era of Highly Effective CFTR Modulators
    Britto, Clemente J.
    Taylor-Cousar, Jennifer L.
    CLINICS IN CHEST MEDICINE, 2022, 43 (04) : XIII - XVI
  • [46] Hyperglycemia and Death in Cystic Fibrosis-Related Diabetes
    Adler, Amanda I.
    Shine, Brian
    Haworth, Charles
    Leelarathna, Lalantha
    Bilton, Diana
    DIABETES CARE, 2011, 34 (07) : 1577 - 1578
  • [47] Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators
    Eldredge, Jessica A.
    Oliver, Mark R.
    Ooi, Chee Y.
    PAEDIATRIC RESPIRATORY REVIEWS, 2024, 50 : 54 - 61
  • [48] The Potential Causes of Cystic Fibrosis-Related Diabetes
    Coderre, Lise
    Debieche, Lyna
    Plourde, Joelle
    Rabasa-Lhoret, Remi
    Lesage, Sylvie
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [49] Ion Channel Modulators in Cystic Fibrosis
    Gentzsch, Martina
    Mall, Marcus A.
    CHEST, 2018, 154 (02) : 383 - 393
  • [50] Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator Modulators
    Burke, Andrew
    Thomson, Rachel M. M.
    Wainwright, Claire E. E.
    Bell, Scott C. C.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 44 (02) : 287 - 296